Remicade, Humira and Enbrel work by blocking an inflammation-causing protein called Tumor Necrosis factor (TNF). Raymond said more than 60 other anti-TNF biosimilars are in development and could commoditize the drug class much sooner than thought.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.